00:00 / 27:45
#1 Introduction
#1
Introduction
#2
Germany's trilemma: a target on its back
01:40
#3
The MFN paradox: revenues, not prices
03:45
#4
Low prices, fast access, strong industry: something has to give
06:40
#5
The UK deal: paying more for access
10:05
#6
A shared bargain for Europe, not a single price
11:45
#7
One bloc or 27 nations? The hidden trade-offs
16:13
#8
The worst outcome: decided by America
20:10
#9
Fair prices and the right indicator
21:58
#10
Health is an investment: key message and conclusion
24:40
"Europe's Access Dilemma" (5/5) - "Germany has a target on its back" What will Europe give up?
"The worst of all outcomes is the current default: the level of Europe's contribution to the world will be decided by America." – Graham Cookson, Economist
Welcome to the 5th episode of Europe's Access Dilemma, the Pharma Minds mini-series on MFN and access to innovation in Europe. Pay more. Wait longer. Or change the model.
Europe wants three things at once: medicines people can afford, fast access to new drugs, and a strong pharma industry. Is that still possible?
My guest is Graham Cookson, Chief Executive of the Office of Health Economics (OHE) in London. He is an econometrician who works on healthcare efficiency, drug pricing and reimbursement. He starts with Germany, the country at the center of MFN.
What you will learn in this episode:
Listen to this episode for a European economist's view of pharma's big picture today: which ways out Europe still has, and what each one will cost.
Ressources
Office of Health Economics (OHE) : https://www.ohe.org
___
📩 Subscribe to the newsletter : https://nathalielahitte.substack.com/
Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.
Powered by Ausha 🚀